A widespread shortage of Adderall and other versions of the drug, used to treat attention deficit hyperactivity disorder (ADHD), is deepening in the United States, leaving desperate patients who use the drug to focus.
Teva Pharmaceuticals Industries Ltd., the largest US manufacturer of Adderall. said last month that labor shortage The Wall Street Journal reports that production has been disrupted since the beginning of the year.
|TEVA||TEVA PHARMACEUTICAL INDUSTRIES LTD.||8.46||-0.20||-2.37%|
A Teva spokeswoman said at the time that the company expected shortages to be resolved at the retail level in the coming weeks, but pharmacies were now reporting shortages of ADHD treatments from several other drugmakers.
The American Society of Health-System Pharmacists (ASHP) this week reported shortages of several versions of amphetamines from multiple manufacturers, saying the low supply is having a nationwide impact on patients unable to fill their prescriptions.
UNITEDHEALTH COMPLETES HEALTHCARE TRANSFORMATION AFTER COURT REJECTS DOJ CHALLENGE
“It scares people,” said Dr. Robert Shulman, a psychiatrist at Rush University Medical Center, told FOX 32 in Chicago. “It’s scary for parents who have kids starting school right now. It’s scary for adults who rely on medicine to get it to them during the week. Patients can’t get their medicine and we get a lot of phone calls. There’s a lot of extra work and patients have to call the pharmacies to see where the supply is.” “
Shulman said several factors are contributing to the shortage, including record prescriptions for the drug after the COVID-19 lockdowns, an increase in recreational use of the stimulant and federally imposed production restrictions.
A spokesperson for Sandoz, the Novartis company that makes the generic version of Adderall, told FOX Business Friday that there is no shortage of its product on the market and that the company is “fulfilling all current customer orders,” but pointed to regulatory factors. can help with drug-related conditions.
BIOGEN SHARES RISE ON ALZHEIMER’S DRUG DEVELOPMENTS
The spokesperson explained that Sandoz, like other drugmakers, forecasts production based on customer pre-orders and is authorized by the company to fulfill the forecast order level. US Drug Enforcement Administration. If the customer orders more than the drug manufacturers predicted due to increased demand, the manufacturers are unable to fulfill these orders and they are considered “back orders”.
Drug companies should apply to the DEA to increase production in this case. Some applications are granted and some are rejected. The DEA did not immediately respond to FOX Business’ request for comment on whether the agency has recently ramped up production for Adderall or plans to do so.
GET THE FOX BUSINESS BY CLICKING HERE
upon arrival FOX Business available for comment, a spokeswoman for the US Food and Drug Administration did not confirm the shortage of Adderall-type drugs, but said the agency “continues to monitor the supply of ADHD drugs.” [is] in contact with manufacturers regarding supplies”.
Leave a Comment